References
- Polsky D, Doshi JA, Bauer MS, et al. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006;163:2047-56
- Edwards NC, Locklear JC, Rupnow MF, et al. Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 2005;23(Suppl 1):75-89
- Edwards NC, Muser E, Doshi D, et al. The threshold rate of oral atypical anti-psychotic adherence at which paliperidone palmitate is cost saving. J Med Econ 2012;15:623-34
- Van Dorn RA, Desmarais SL, Petrila J, et al. Effects of outpatient treatment on risk of arrest of adults with serious mental illness and associated costs. Psychiatr Serv 2013;64:856-62
- Lin I, Muser E, Munsell M, et al. Economic impact of psychiatric relapse and recidivism among adults with schizophrenia recently released from incarceration: a Markov model analysis. J Med Econ 2015;18:219-29
- Benson C, Dickson WM, Kozma CM, et al. Relationship between Medicaid eligibility and time to re-incarceration of previously incarcerated schizophrenia diagnosed subjects [abstract]. Value Health 2014;17:A151
- Petrila J, Andel R, Constantine R, et al. Public expenditures related to the criminal justice system and to services for arrestees with a serious mental illness. Psychiatr Serv 2010;61:516-19
- Torrey EF, Kennard AD, Eslinger D, et al. Treatment Advocacy Center. More Mentally Ill Persons Are in Jails and Prisons Than Hospitals: A Survey of the States. 2010. Available at: http://www.treatmentadvocacycenter.org/storage/documents/final_jails_v_hospitals_study.pdf [Last accessed 8 April 2015]
- Alphs L, Mao L, Rodriguez SC, et al. Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study: a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia. J Clin Psychiatry 2014;75:1388-93
- Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review boardblinded 15-month study. J Clin Psychiatry. 2015. Prepublished on April 14, 2015 as doi:10.4088/JCP.14m09584
- Muser E, Benson C, Kozma C, et al. Estimating costs related to health resource utilization and contacts with the criminal justice system for patients diagnosed with schizophrenia [abstract and poster 308]. In: 26th Annual US Psychiatric and Mental Health Congress. Las Vegas, NV, USA, 2013
- Kozma CM, Muser E, Benson C. Baseline health resource and criminal justice system costs for clinical trial subjects with schizophrenia and prior incarceration. Value Health 2014;17:A218
- Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation (Handbooks in Health Economic Evaluation). Oxford: Oxford University Press, 2006
- Cohen MA, Rust RT, Steen S. National Institute of Justice (US). Measuring public perceptions of appropriate prison sentences: excutive summary. Washington, DC, 2003. Available at: https://www.ncjrs.gov/pdffiles1/nij/grants/199364.pdf [Last accessed 8 April 2015]